Having trouble accessing articles? Reset your cache.
In an ongoing, double-blind, placebo-controlled, U.S. Phase II trial in 95 patients, all 6 patients who received 200 mg ANA598 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus
Get a two-week free trial subscription to BioCentury